Literature DB >> 26344572

Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases.

Jing Fu1, Erik Pacyniak1, Marina G D Leed1, Matthew P Sadgrove1, Lesley Marson1, Michael Jay2.   

Abstract

The pentaethyl ester prodrug of the chelating agent diethylene triamine pentaacetic acid (DTPA) referred to as C2E5 is being developed as an orally bioavailable radionuclide decorporation agent. The predicted human efficacy obtained in these experimental animals is confounded by interspecies variations of metabolism. Therefore, in the present study, carboxylesterase-mediated metabolism of [(14)C]-C2E5 was compared in the S9 intestinal and hepatic fractions of human, dog, and rat and their respective plasma. Intestinal hydrolysis of C2E5, resulting in the formation of the tetraethyl ester of DTPA (C2E4), was only detected in human and rat. The primary metabolite in human and dog hepatic fractions was C2E4, whereas the predominant species identified in rat hepatic fractions was the triethyl ester (C2E3). Hepatic hydrolysis of C2E5 causes the formation of C2E4 in human, dog, and rat and C2E3 in rat only. Minimal C2E5 hydrolysis was observed in human and dog plasma, whereas in rat plasma C2E5 converted to C2E3 rapidly, followed by slower further metabolism. Both recombinant CES1 and CES2 play roles in C2E5 metabolism. Together, these data suggest that dogs may be the most appropriate species for predicting human C2E5 metabolism, whereas rats might be useful for clarifying the potential toxicity of C2E5 metabolites.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  HPLC (high-performance/pressure liquid chromatography); enzymes; hepatic metabolism; intestinal metabolism; metabolism; prodrugs

Mesh:

Substances:

Year:  2016        PMID: 26344572      PMCID: PMC4781669          DOI: 10.1002/jps.24632

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  28 in total

1.  Current progress on esterases: from molecular structure to function.

Authors:  Tetsuo Satoh; Palmer Taylor; William F Bosron; Sonal P Sanghani; Masakiyo Hosokawa; Bert N La Du
Journal:  Drug Metab Dispos       Date:  2002-05       Impact factor: 3.922

Review 2.  Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.

Authors:  Kevin Beaumont; Robert Webster; Iain Gardner; Kevin Dack
Journal:  Curr Drug Metab       Date:  2003-12       Impact factor: 3.731

3.  Glycolamide esters as biolabile prodrugs of carboxylic acid agents: synthesis, stability, bioconversion, and physicochemical properties.

Authors:  N M Nielsen; H Bundgaard
Journal:  J Pharm Sci       Date:  1988-04       Impact factor: 3.534

4.  Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.

Authors:  Sonal P Sanghani; Sara K Quinney; Tyler B Fredenburg; Wilhelmina I Davis; Daryl J Murry; William F Bosron
Journal:  Drug Metab Dispos       Date:  2004-05       Impact factor: 3.922

5.  Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs.

Authors:  M Inoue; M Morikawa; M Tsuboi; M Sugiura
Journal:  Jpn J Pharmacol       Date:  1979-02

6.  Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver.

Authors:  Toshiki Tabata; Miki Katoh; Shogo Tokudome; Miki Nakajima; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2004-07-21       Impact factor: 3.922

7.  Comparison of enzymatic hydrolysis of pilocarpine prodrugs in human plasma, rabbit cornea, and butyrylcholinesterase solutions.

Authors:  T Järvinen; M Poikolainen; P Suhonen; J Vepsäläinen; S Alaranta; A Urtti
Journal:  J Pharm Sci       Date:  1995-05       Impact factor: 3.534

Review 8.  Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism.

Authors:  Lucio G Costa; Toby B Cole; Gail P Jarvik; Clement E Furlong
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

9.  Esterase-like activity of serum albumin: characterization of its structural chemistry using p-nitrophenyl esters as substrates.

Authors:  Yuji Sakurai; Shen-Feng Ma; Hiroshi Watanabe; Noriyuki Yamaotsu; Shuichi Hirono; Yukihisa Kurono; Ulrich Kragh-Hansen; Masaki Otagiri
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 10.  Paraoxonase, a cardioprotective enzyme: continuing issues.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Curr Opin Lipidol       Date:  2004-06       Impact factor: 4.776

View more
  5 in total

1.  Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.

Authors:  Lukáš Tenora; Jesse Alt; Ranjeet P Dash; Alexandra J Gadiano; Kateřina Novotná; Vijayabhaskar Veeravalli; Jenny Lam; Quinn R Kirkpatrick; Kathryn M Lemberg; Pavel Majer; Rana Rais; Barbara S Slusher
Journal:  J Med Chem       Date:  2019-03-29       Impact factor: 7.446

2.  Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.

Authors:  Xuan Ding; Jeffrey S Day; David C Sperry
Journal:  AAPS J       Date:  2016-07-12       Impact factor: 4.009

3.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.

Authors:  Robert D Leone; Liang Zhao; Judson M Englert; Im-Meng Sun; Min-Hee Oh; Im-Hong Sun; Matthew L Arwood; Ian A Bettencourt; Chirag H Patel; Jiayu Wen; Ada Tam; Richard L Blosser; Eva Prchalova; Jesse Alt; Rana Rais; Barbara S Slusher; Jonathan D Powell
Journal:  Science       Date:  2019-11-07       Impact factor: 47.728

4.  N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.

Authors:  Michael T Nedelcovych; Lukáš Tenora; Boe-Hyun Kim; Jennifer Kelschenbach; Wei Chao; Eran Hadas; Andrej Jančařík; Eva Prchalová; Sarah C Zimmermann; Ranjeet P Dash; Alexandra J Gadiano; Caroline Garrett; Georg Furtmüller; Byoungchol Oh; Gerald Brandacher; Jesse Alt; Pavel Majer; David J Volsky; Rana Rais; Barbara S Slusher
Journal:  J Med Chem       Date:  2017-08-14       Impact factor: 8.039

5.  Rapid bioluminescence assay for monitoring rat CES1 activity and its alteration by traditional Chinese medicines.

Authors:  Jun Zhang; Dandan Wang; Liwei Zou; Min Xiao; Yufeng Zhang; Ziwei Li; Ling Yang; Guangbo Ge; Zhong Zuo
Journal:  J Pharm Anal       Date:  2020-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.